These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22285208)

  • 21. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
    Schneiderman J; Nugent DJ; Young G
    Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
    Astermark J; Donfield SM; DiMichele DM; Gringeri A; Gilbert SA; Waters J; Berntorp E;
    Blood; 2007 Jan; 109(2):546-51. PubMed ID: 16990605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current opinion on inhibitor treatment options.
    Mathew P
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
    Holmberg HL; Lauritzen B; Tranholm M; Ezban M
    J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
    Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J
    Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
    Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
    Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global Hemostatic Methods to Tailor Treatment With Bypassing Agents in Hemophilia A With Inhibitors- A Single-Center, Pilot Study.
    Chaireti R; Soutari N; Holmström M; Petrini P; Magnusson M; Ranta S; Pruner I; Antovic JP
    Clin Appl Thromb Hemost; 2024; 30():10760296241260053. PubMed ID: 39051565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study.
    Mingot-Castellano ME; García-Candel F; Benítez-Hidalgo O; Marco A; Méndez Navarro GA; Pérez-Montes R; García Donas G; Canaro M; Paloma MJ; Asenjo B; Calle-Gordo VM; González NP; Rodríguez González R; Caparrón-Miranda IS; Quintana París L; Herrero S; Nuñez R
    Eur J Haematol; 2022 Dec; 109(6):686-695. PubMed ID: 36029160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
    Ogiwara K; Nogami K; Matsumoto T; Shima M
    Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
    Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
    Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
    Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP
    Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Articular Bleeding in Hemophilia.
    Rodriguez-Merchan EC
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):21-24. PubMed ID: 28049407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.